The DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Comparative Risk for Harms of Second-Generation Antidepressants: A Systematic Review and Meta-Analysis
Abstract
Background Evidence indicates that only minor differences in efficacy exist among second-generation antidepressants for the treatment of major depressive disorder (MDD). However, a comprehensive assessment of both benefits and harms is crucial to evaluate the net benefit.Objective To review systematically the comparative harms of second-generation antidepressants for the treatment of MDD in adults by including both experimental and observational evidence.Data sources We searched MEDLINE, EMBASE, PsychLit, The Cochrane Library and the International Pharmaceutical Abstracts from 1980 to April 2007. We manually searched reference lists of pertinent review articles and explored the Center for Drug Evaluation and Research database to identify unpublished research.Study selection Eligible study designs were trials and observational studies comparing one drug of interest with another.Data extraction Two persons independently reviewed abstracts and full-text articles. One investigator extracted relevant data. A senior reviewer checked data for completeness and accuracy.Data synthesis We included 104 experimental and observational studies. If data were sufficient, we conducted meta-analyses of randomized controlled trials on the relative risk of specific adverse events. Findings indicate that the spectrum of adverse events is similar. The frequency of specific adverse events, however, differed across drugs. Venlafaxine was associated with a significantly higher rate of nausea and vomiting than selective serotonin reuptake inhibitors. Compared with other drugs, paroxetine frequently led to more sexual adverse effects and bupropion to fewer such effects; mirtazapine and paroxetine was associated with more weight gain and sertraline with a higher rate of diarrhoea. Overall, however, these differences did not lead to different discontinuation rates. The evidence is insufficient to draw conclusions about rare but severe adverse events.Conclusions Adverse event profiles are similar among second-generation antidepressants. However, different frequencies of specific adverse events might be clinically relevant and influence the choice of a treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“around 60% of patients using second-generation antidepressants, such as selective serotonin reuptake inhibitors [SSRIs] encountered adverse events, and 7% to 15% quit treatment due to the events (Gartlehner et al. 2008)”
From A Scoping Review of Correctional-Based Interventions for Women Prisoners with Mental Health Problems (2023) · cites this paper as Gartlehner et al. 2008
In the citing paper
“A meta-analysis further showed that the relative risk of nausea and vomiting for venlafaxine was higher than those for SSRIs with RR of 1.53 (95% CI, 1.26–1.86).44”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [44]
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Current methods of the U.S. Preventive Services Task Force
Harris, R., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. C. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,720
Self-citationSystematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Antidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 587
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico‐Villademoros, F. (2001) · PubMed · Cited by 460
Antidepressants and the Risk of Falls among Nursing Home Residents
Thapa, P. B., Gideon, P. S., Cost, T. W., Milam, A. B., & Ray, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391303 · Cited by 437
Williams, J. W., Mulrow, C. D., Chiquette, E., Noël, P. H., Aguilar, C., & Cornell, J. E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00011 · Cited by 419
Khan, A., Khan, S., Kolts, R. L., & Brown, W. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.790 · Cited by 393
Buckley, N. A., & McManus, P. R. (2002) · BMJ · doi:10.1136/bmj.325.7376.1332 · Cited by 380
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I. P., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 354
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 7×
“…et al., 2007[116] 684 8 weeks Escitalopram 10 Duloxetine 60 81 vs. 86 Higher rates of nausea with duloxetine (24 vs. 12) No differences Fair Goldstein et al., 2002[117] 173 8 weeks Fluoxetine 20 Duloxetine 40-120 NR Higher rates of headache (33 vs. 20), diarrhea (30 vs. 14), and nausea…”
BackgroundInfluentialSerotonin Syndrome Presentation of 2 Cases and Review of the Literature
Mason, P. J., Morris, V. A., & Balcezak, T. J. (2000) · Medicine · doi:10.1097/00005792-200007000-00001 · Cited by 311
Similar Effectiveness of Paroxetine, Fluoxetine, and Sertraline in Primary Care
Kroenke, K., West, S. L., Swindle, R. W., Gilsenan, A., Eckert, G. J., Dolor, R. J., Stang, P., Zhou, X., Hays, R. D., & Weinberger, M. (2001) · JAMA · doi:10.1001/jama.286.23.2947 · Cited by 310
Anderson, I. M., & Tomenson, B. (1995) · BMJ · doi:10.1136/bmj.310.6992.1433 · Cited by 307
Clerc, G. E., Ruimy, P., & Verdeau-Pailles, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 301
Liu, B. A., Mittmann, N., Knowles, S. R., & Shear, N. H. (1996) · Europe PMC (PubMed Central) · Cited by 290
Detke, M. J., Wiltse, C. G., Mallinckrodt, C. H., McNamara, R. K., Demitrack, M. A., & Bitter, I. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.01.002 · Cited by 285
Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder
D, M. F. M., Judge, R., HOOG, S. L., Nilsson, M., & Koke, S. C. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1109 · Cited by 266
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 260
Self-citationSelective serotonin reuptake inhibitors
Montgomery, S. A., Henry, J. A., McDonald, G. J., Dinan, T. G., LADER, M. H., Hindmarch, I., Clare, A. W., & Nutt, D. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400910-00008 · Cited by 254
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Jick, S. S., Dean, A. D., & Jick, H. (1995) · BMJ · doi:10.1136/bmj.310.6974.215 · Cited by 248
Silverstone, P. H., Ravindran, A. V., & the Venlafaxine XR 360 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0105 · Cited by 246
Croft, H. A., Settle, E. C., Houser, T. L., Batey, S. R., Donahue, R. M. J., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88317-4 · Cited by 244
Martínez, C., Rietbrock, S., Wise, L., Ashby, D., Chick, J., Moseley, J., Evans, S. J. W., & Gunnell, D. (2005) · BMJ · doi:10.1136/bmj.330.7488.389 · Cited by 239
Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg062 · Cited by 228
Kennedy, S. H., Eisfeld, B. S., Dickens, S. E., Bacchiochi, J. R., & Bagby, R. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0406 · Cited by 223
Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., & Murphy, G. M. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200209000-00007 · Cited by 215
Rush, A. J., Armitage, R., Gillin, J. C., Yonkers, K. A., Winokur, A., Moldofsky, H., Vogel, G. W., Kaplita, S. B., Fleming, J. B., Montplaisir, J., et al. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00092-4 · Cited by 215
A simple and valid tool distinguished efficacy from effectiveness studies
Gartlehner, G., Hansen, R. A., Nissman, D., Lohr, K. N., & Carey, T. S. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.011 · Cited by 207
Self-citationMoore, N. D., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 190
Feiger, A. D., Kiev, A., Shrivastava, R. K., Wisselink, P., & Wilcox, C. S. (1996) · PubMed · Cited by 185
Dunner, D. L., Zisook, S., Billow, A. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0705 · Cited by 180 · cited 3×
“Table S4: Study characteristics, main findings, and quality ratings of observational studies and open-label trials Study Design, Interventions N Results Quality Rating General Tolerability and Discontinuation Mackay et al., 1997, 1999[42, 43] Prescription event monitoring, Fluoxetine, fluvoxamine, nefazodone, paroxeti…”
BackgroundInfluentialBielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Szegedi, A., Müller, M. J., Anghelescu, I. G., Klawe, C., Kohnen, R., & Benkert, O. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0410 · Cited by 174
Antidepressants and the serotonin syndrome in general practice.
Mackay, F. J., Dunn, N. R., & Mann, R. D. (1999) · PubMed · Cited by 172
Coleman, C. C., King, B., Bolden-Watson, C., Book, M. J., Segraves, R., Richard, N., Ascher, J., Batey, S. R., Jamerson, B., & Metz, A. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80090-4 · Cited by 171
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
A Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158 · cited 1×
“, 1999([49]) 301 8 weeks Fluoxetine 20-60 Venlafaxine 75225 NR Higher rates of nausea (36 vs.”
BackgroundWheatley, D. P., Moffaert, M. V., Timmerman, L., & Kremer, C. M. E. (1998) · PubMed · Cited by 157
Mirtazapine Compared With Paroxetine in Major Depression
Benkert, O., Szegedi, A., & Kohnen, R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0911 · Cited by 157
Dieric, M., Ravizza, U., Realini, R., & Martin, A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00292-8 · Cited by 152
A 102-center prospective study of seizure in association with bupropion.
Johnston, J. A., Lineberry, C. G., Ascher, J. A., Davidson, J. R. T., Khayrallah, M. A., Feighner, J. P., & Stark, P. (1991) · PubMed · Cited by 151
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150
Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients
Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1204 · Cited by 149
Kirby, D., Harrigan, S., & Ames, D. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.591 · Cited by 149
Leinonen, E., Skarstein, J., Behnke, K., ??gren, H., & Th Helsdingen, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00002 · Cited by 146
Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F. (2002) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.10.5.541 · Cited by 146
Wheatley, D. P., van Moffaert, M., Timmerman, L., Kremer, C. M. E., & The Mirtazapine-Fluoxetine Study Group (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0606 · Cited by 145
Schatzberg, A. F., & Roose, S. P. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000194645.70869.3b · Cited by 143
Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
Guelfi, J. D., Ansseau, M., Timmerman, L., & Kørsgaard, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00010 · Cited by 138
Delgado, P. L., Brannan, S. K., Mallinckrodt, C. H., Trân, P. V., McNamara, R. K., Wang, F., Watkin, J. G., & Detke, M. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0603 · Cited by 135
Nierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167453 · Cited by 132
Coleman, C. C., Cunningham, L. A., Foster, V. J., Batey, S. R., Donahue, R. M. J., Houser, T. L., & Ascher, J. A. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022309428886 · Cited by 131
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
David, P., Wang, F., Mallinckrodt, C. H., Walker, D. J., & Detke, M. J. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.03.004 · Cited by 128
D, M. F. M., Rosenbaum, J. F., HOOG, S. L., Tepner, R. G., Kopp, J. B., & Nilsson, M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00131-7 · Cited by 126
Lindström, E., Lewander, T., Malm, U., Malt, U. F., Lublin, H., & Ahlfors, U. G. (2001) · Nordic Journal of Psychiatry · doi:10.1080/080394801317084428 · Cited by 124
Escitalopram in the Treatment of Depressed Elderly Patients
Kasper, S. F., de Swart, H., & Andersen, H. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.884 · Cited by 124
Cassano, G. B., Puca, F., Scapicchio, P. L., Trabucchi, M., & Italian Study Group on Depression in Elderly Patients (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0504 · Cited by 121 · cited 7×
“, 2002([102]) 242 52 weeks Fluoxetine 20-60 Paroxetine 20-40 33 vs.”
BackgroundInfluentialRubino, A., Roskell, N., Tennis, P., Mines, D. I., Weich, S., & Andrews, E. B. (2006) · BMJ · doi:10.1136/bmj.39041.445104.be · Cited by 121
Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine
Thase, M. E., Trân, P. V., Wiltse, C. G., Pangallo, B. A., Mallinckrodt, C. H., & Detke, M. J. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155815.44338.95 · Cited by 118
Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study
Behnke, K., Søgaard, J., Martin, S. D., Bäuml, J., Ravindran, A. V., Ågren, H., & Vester-Blokland, E. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085408.08426.05 · Cited by 115
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T. A., & Sarchiapone, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115513 · Cited by 112
Wilde, J. D., Spiers, R., Mertens, C., Bartholomé, F., Schotte, G., & Leyman, S. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03345.x · Cited by 111
Reemergence of Sexual Dysfunction in Patients With Major Depressive Disorder
Ferguson, J. M., Shrivastava, R. K., Stahl, S. M., Hartford, J. T., Borian, F. E., Ieni, J. R., McQuade, R. D., & Jody, D. N. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0106 · Cited by 109
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., & Lineberry, C. G. (1991) · PubMed · Cited by 107
Comparison of Bupropion and Trazodone for the Treatment of Major Depression
Weisler, R. H., Johnston, J., Lineberry, C. G., Samara, B., Branconnier, R. J., & Billow, A. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00004 · Cited by 107
Allard, P. O., Gram, L. F., Timdahl, K., Behnke, K., Hanson, M., & Søgaard, J. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1190 · Cited by 106
(1995) · PubMed · Cited by 105
Coleman, C., Cunningham, L., Foster, V., et al. (1999) · Annals of Clinical Psychiatry · doi:10.3109/10401239909147072 · Cited by 105
Mehtonen, O. ‐., Søgaard, J., Roponen, P., Behnke, K., & Venlafaxine 631 Study Group (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0204 · Cited by 97
Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients
Halikas, J. A. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100807 · Cited by 96
Silva, J. C. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0703 · Cited by 95
Åberg‐Wistedt, A., Ågren, H., Ekselius, L., Bengtson, F., & Åkerblad, A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00010 · Cited by 95
NE, W. S., & LUDWIG, M. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312002-00006 · Cited by 95
Sexual Function during Bupropion or Paroxetine Treatment of Major Depressive Disorder
Kennedy, S. H., Fulton, K., Bagby, R. M., Greene, A. L., Cohen, N. L., & Rafi‐Tari, S. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100405 · Cited by 94
A Double-blind Comparison Between Bupropion XL and Venlafaxine XR
Thase, M. E., Clayton, A. H., Haight, B. R., Thompson, A. H., Modell, J. G., & Johnston, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239790.83707.ab · Cited by 93
Ekselius, L., von Knorring, L., & Eberhard, G. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00005 · Cited by 92
D, M. F. M., HOOG, S. L., Judge, R., Kopp, J. B., Nilsson, M., & Gonzales, J. S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00006 · Cited by 90
Segraves, R. T., Kavoussi, R. J., Hughes, A. R., Batey, S. R., Johnston, J. A., Donahue, R. M. J., & Ascher, J. A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00002 · Cited by 90
(1991) · PubMed · Cited by 89
A Double-Blind Comparison of Fluvoxamine and Paroxetine in the Treatment of Depressed Outpatients
Kiev, A., & Feiger, A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0402 · Cited by 89
Patris, M., Bouchard, J. M., Bougerol, T., Jf, C., Chevalier, J.-F., Clerc, G., Cyran, C., Amerongen, P. V., Lemming, O. M., & Petersen, H. E. H. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606000-00007 · Cited by 85
Hicks, J. A., Argyropoulos, S. V., Rich, A. S., Nash, J., Bell, C. J., Edwards, C., Nutt, D. J., & Wilson, S. J. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.6.528 · Cited by 84
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression
D, M. F. M., Amsterdam, J. D., Deltito, J. A., Salzman, C., Schwaller, M., & Dünner, D. L. (1998) · Annals of Clinical Psychiatry · doi:10.1023/a:1022337927842 · Cited by 82
Landén, M., Högberg, P., & Thase, M. E. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0114 · Cited by 82
Colonna, L., Andersen, H. F., & Reines, E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65484 · Cited by 82
Hepatic Adverse Reactions Associated with Nefazodone
Stewart, D. E. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700409 · Cited by 80
Tzanakaki, M., Guazzelli, M., Nimatoudis, I., & Zissis, N. P. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00004 · Cited by 80
Baldwin, D. S., Hawley, C. J., Abed, R. T., Maragakis, B. P., Cox, J. L., Buckingham, S. A., Pover, G. H., & Ascher, A. (1996) · PubMed · Cited by 79
Moffaert, M. V., Wilde, J. D., Vereecken, A., Dierick, M., Evrard, J.-L., Wilmotte, J., & MENDLEWICZ, J. (1995) · PubMed · Cited by 77
Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients
Versiani, M., Moreno, R. A., van Moorsel, C. J. A., Schutte, A. J., & Study, C. E. O. A. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00004 · Cited by 76
Gartlehner, G., Hansen, R. A., Thieda, P., DeVeaugh‐Geiss, A., Gaynes, B. N., Krebs, E. E., Lux, L. J., Morgan, L. C., Shumate, J., Monroe, L. G., et al. (2007) · Europe PMC (PubMed Central) · Cited by 76
Self-citationEkselius, L., & von Knorring, L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00006 · Cited by 75
Tignol, J. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312002-00003 · Cited by 71
Are All Antidepressants Really the Same? The Case of Fluoxetine
Cipriani, A., Barbui, C., Brambilla, P., Furukawa, T. A., Hotopf, M. H., & Geddes, J. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0601 · Cited by 71
Comparative Efficacy of Sertraline vs. Fluoxetine in Patients Age 70 or Over With Major Depression
Finkel, S. I., Richter, E. M., Clary, C. M., & Batzar, E. D. (1999) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199908000-00006 · Cited by 70
Mirtazapine is more effective than trazodone
Moffaert, M. V., Wilde, J. E. D., Vereecken, A., Dierick, M., Evrard, J.-L., Wilmotte, J., & Mendlewicz, J. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503000-00001 · Cited by 68
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety
Nayer, A. D., Geerts, S., Ruelens, L., Schittecatte, M., Bleeker, E. D., Eeckhoutte, I. V., Evrard, J.-L., Linkowski, P., Fossion, P., Leyman, S., et al. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002857 · Cited by 67
Ballús, C., Quiros, G., de Flores, T., de la Torre, J., Palao, D. J., Rojo, L., Gutiérrez, M., Casais, L., & Riesgo, Y. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00007 · Cited by 65
Zervanos, N. J. (1998) · The Journal of the American Board of Family Medicine · doi:10.3122/15572625-11-2-174 · Cited by 64
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression
Fava, M., Amsterdam, J. D., Deltito, J. A., et al. (1998) · Annals of Clinical Psychiatry · doi:10.3109/10401239809147030 · Cited by 63
Ventura, D., Armstrong, E. P., Skrepnek, G. H., & Erder, M. H. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x167273 · Cited by 62
Nemeroff, C. B., & Thase, M. E. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.07.009 · Cited by 62
Loke, Y. K., Derry, S., & Aronson, J. K. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.0306-5251.2003.02055.x · Cited by 60
Sechter, D., Troy, S., Paternetti, S., & Boyer, P. (1999) · European Psychiatry · doi:10.1016/s0924-9338(99)80714-7 · Cited by 59
Didham, R. C., McConnell, D. W., Blair, H. J., & Reith, D. M. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02480.x · Cited by 59
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder
Chouinard, G., Saxena, B., Bélanger, M.-C., Ravindran, A., Bakish, D., Beauclair, L., Morris, P., Vasavan Nair, N. P., Manchanda, R., Reesal, R., et al. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00188-8 · Cited by 57
Newer antidepressants: a comparison of tolerability in general practice.
Mackay, F. R., Dunn, N. R., Martin, R. M., Pearce, G. L., Freemantle, S. N., & Mann, R. D. (1999) · Europe PMC (PubMed Central) · Cited by 53
Kasper, S. F., Olivieri, L., Loreto, G. D., & Dionisio, P. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x53243 · Cited by 52
Nemeroff, C. B., Ninan, P. T., Ballenger, J., Lydiard, R. B., Feighner, J. P., Patterson, W. M., & Greist, J. H. (1995) · Depression · doi:10.1002/depr.3050030402 · Cited by 52
Rush, A. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00249-9 · Cited by 52
Moffaert, M. V., Bartholomé, F., Cosyns, P. R., Nayer, A. R. D., & Mertens, C. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100505 · Cited by 51
Shelton, R. C., Haman, K., Rapaport, M. H., Kiev, A., Smith, W. T., Hirschfeld, R. M. A., Lydiard, R. B., Zajecka, J., & Dünner, D. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1102 · Cited by 51
Munizza, C., Olivieri, L., Loreto, G. D., & Dionisio, P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x121039 · Cited by 51
Hong, C., Hu, W.-H., Chen, C.-C., Hsiao, C., Tsai, S., & Ruwe, F. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0810 · Cited by 50
Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of Depression
Boyer, P., Danion, J., Bisserbe, J. C., Hotton, J., & Troy, S. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813010-00015 · Cited by 49
A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major Depression
Rapaport, M. H., Coccaro, E. F., Sheline, Y. I., Perse, T., Holland, P. J., Fabre, L. F., & Bradford, D. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00005 · Cited by 49
Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression
Rossini, D., Serretti, A., Franchini, L., Mandelli, L., Smeraldi, E., Ronchi, D. D., & Zanardi, R. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000177548.28961.e7 · Cited by 44
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients
Haffmans, P. M. J., Timmerman, L., & Hoogduin, C. A. L. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199609000-00002 · Cited by 44
A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
Perry, P. J., Garvey, M. J., Kelly, M. W., Cook, B. L., Dunner, F. J., & Winokur, G. (1989) · PubMed · Cited by 40
Philipp, M., Tiller, J. W. G., Baier, D., & Kohnen, R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00085-7 · Cited by 40
Fluvoxamine versus fluoxetine in major depressive episode: a double‐blind randomised comparison
Jean Dalery, A., & Honig, A. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.490 · Cited by 40
Lancet, T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16080-7 · Cited by 38
Krebs, E. E., Gaynes, B. N., Gartlehner, G., Hansen, R. A., Thieda, P., Morgan, L. C., DeVeaugh‐Geiss, A., & Lohr, K. N. (2008) · Psychosomatics · doi:10.1176/appi.psy.49.3.191 · Cited by 35
Self-citationEfficacy and tolerability of second-generation antidepressants in social anxiety disorder
Hansen, R. A., Gaynes, B. N., Gartlehner, G., Moore, C. G., Tiwari, R., & Lohr, K. N. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f4224a · Cited by 35
Self-citationEfficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
Figueira, M. L., Arriaga, F., Lara, E., Albuquerque, A. J., & Gamito, L. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80184-3 · Cited by 33
McPartlin, G., Reynolds, A., Anderson, C. C., Casoy, J., & Boyd, M. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)88532-x · Cited by 33
Meijer, W. E. E., Heerdink, E. R., van Eijk, J. T. M., & Leufkens, H. G. M. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.752 · Cited by 30
Characterizing the ideal antidepressant therapy to achieve remission.
Ferrier, I. N. (2001) · PubMed · Cited by 21
Renal disease and acid-suppressing drugs
Rodriguez, L. A. G., Wallander, M.-A. A., Johanson, S., & Björck, S. (1997) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199707)6:4 · Cited by 3
Research works printed but not linked: 16
- Gartlehner, 2006, J Clin Epidemiol, 60, 753
- Feighner, 1991, J Clin Psychiatry, 52, 329
- Tylee, 1997, Primary Care Psychiatry, 3, 51
- Alves, 1999, Primary Care Psychiatry, 5, 57
- Bennie, 1995, J Clin Psychiatry, 56, 229
- Beasley Jr, 1991, J Clin Psychiatry, 52, 294
- Cunningham, 1994, JClin Psychopharmacol, 14, 99
- Perry, 1989, J Clin Psychiatry, 50, 290
- Lepola, 2003, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
- Patris, 1996, Int Clin Psychopharmacol, 11, 129
- Kasper, 2005, Am J Geriatr Psychiatry, 13, 884, 10.1097/00019442-200510000-00008 · DOI
- Gagiano, 1993, Br J Clin Res, 4, 145
- Johnston, 1991, J Clin Psychiatry, 52, 450
- Mackay, 1999, Br J Gen Pract, 49, 892
- Mackay, 1999, Br J Gen Pract, 49, 871
- Liu, 1996, CMAJ, 155, 519
Cited by
Sorted by citations
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“It is important to note that there is considerable variability among antidepressants in the nature and severity of side-effects, and these also vary from one individual to another (Gartlehner et al., 2008, 2011).”
BackgroundDepression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 529
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Metadata
- Authors
- Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N.
- Affiliations
- Universität für Weiterbildung Krems (AT)
- University of North Carolina at Chapel Hill (US)
- Regenstrief Institute (US)
- RTI International (US)
- Corresponding author
- Gartlehner, Gerald
- Venue
- Drug Safety
- Published
- 2008
- Volume
- 31
- Issue
- 10
- Pages
- 851-865
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2006078781
- Cited by
- 150
- References
- 141
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 7 · 2013: 11 · 2012: 10
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (290-02-0016)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- second-generation antidepressants, major depressive disorder, adverse drug reactions, drug safety comparison, venlafaxine, selective serotonin reuptake inhibitors, paroxetine, bupropion, mirtazapine, sertraline, sexual adverse effects, weight gain, nausea and vomiting, diarrhea, discontinuation rate, net benefit
- MeSH terms
- Adult, Blood Pressure, Depressive Disorder, Major, Major Depressive Disorder, Humans, Nausea, Seizures, Sexual Dysfunction, Physiological, Vomiting, Treatment Outcome, Risk Assessment, Antidepressive Agents, Second-Generation, Sexual Dysfunctions, Psychological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review